Abiraterone Acetate

Summary

Abiraterone Acetate (CHEMBL271227) is an approved small-molecule prodrug; indicated across 12 conditions including prostate carcinoma and prostate adenocarcinoma; with CIViC clinical evidence for 2 variant-indication associations (e.g. AR AR-V7 in salivary gland cancer).

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Indications: 12 conditions
• Clinical trials: 298
• Precision-oncology evidence (CIViC): 2 variant–indication associations
• Chemistry: 391.5 Da · C26H33NO2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL271227
Name	Abiraterone Acetate
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	9821849
ChEBI	CHEBI:68639
Molecular formula	C26H33NO2
Molecular weight	391.5
InChIKey	UVIQSJCZCSLXRZ-UBUQANBQSA-N

SMILES: CC(=O)O[C@H]1CC[C@@]2([C@H]3CC[C@]4([C@H]([C@@H]3CC=C2C1)CC=C4C5=CN=CC=C5)C)C

IUPAC name: [(3S,8R,9S,10R,13S,14S)-10,13-dimethyl-17-pyridin-3-yl-2,3,4,7,8,9,11,12,14,15-decahydro-1H-cyclopenta[a]phenanthren-3-yl] acetate

ChEBI definition: A sterol ester obtained by formal condensation of the 3-hydroxy group of abiraterone with the carboxy group of acetic acid. A prodrug that is converted in vivo into abiraterone. Used for treatment of metastatic castrate-resistant prostate cancer.

Pharmacological roles (ChEBI): prodrug, antineoplastic agent, EC 1.14.99.9 (steroid 17α-monooxygenase) inhibitor.

Also known as: Abiraterone accord, Abiraterone acetate, Abiraterone acetate component of akeega, Abiraterone krka, Abiraterone mylan, CB-7630, CB7630, NSC-748121, NSC-749227, Yonsa, Zytiga, abiraterone acetate

Patent coverage: 1,156 distinct patent families (2,610 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 2,234 (86%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 3 (assay-derived). Sample: Androgen receptor, Progesterone receptor, Steroid 17-alpha-hydroxylase/17,20 lyase.

Bioactivity

ChEMBL activities: 5 potent at pChembl ≥ 5 of 6 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
CYP17A1	8.6	IC50	2.5	nM	CHEMBL_ACT_25828651
CYP17A1	7.82	IC50	15	nM	CHEMBL_ACT_25828652
CYP17A1	7.77	IC50	17	nM	CHEMBL_ACT_956426
CYP17A1	7.75	IC50	18	nM	CHEMBL_ACT_956427
PGR	5.51	AC50	3100	nM	CHEMBL_ACT_25192893

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

12 indications (4 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
prostate carcinoma	4	MONDO:0005159	EFO:0001663
prostate adenocarcinoma	4	MONDO:0005082	EFO:0000673
metastatic prostate carcinoma	4	MONDO:0004956	EFO:0000196
prostate cancer	4	MONDO:0008315	MONDO:0008315
breast neoplasm	3	MONDO:0021100	MONDO:0007254
salivary gland cancer	2	MONDO:0004669	EFO:0003826
congenital adrenal hyperplasia	2	MONDO:0018479	MONDO:0008728
liver disorder	1	MONDO:0005154	EFO:0001421
non-small cell lung carcinoma	1	MONDO:0005233	EFO:0003060
kidney failure	1	MONDO:0001106	HP:0000083
neoplasm	1	MONDO:0005070	MONDO:0004992

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 298.

Phase distribution

Phase	Trials
PHASE2	137
PHASE1	52
PHASE3	40
PHASE1/PHASE2	32
Not specified	24
PHASE4	6
PHASE2/PHASE3	4
EARLY_PHASE1	3

Top trials by phase / activity

NCT	Phase	Status	Title
NCT03016741	PHASE4	ACTIVE_NOT_RECRUITING	Cognitive Effects of Androgen Receptor Directed Therapies for Advanced Prostate Cancer
NCT05457257	PHASE4	ACTIVE_NOT_RECRUITING	Clinical Study to Assess the Efficacy and Safety of Olaparib in Chinese Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Prior Treatment With a New Hormonal Agent and Have BRCA1/2 Mutations
NCT07001709	PHASE4	RECRUITING	Determining the Effect of Abiraterone on the Metabolism of Oxycodone in Men With Prostate Cancer (the ENABLE Study)
NCT01995513	PHASE4	COMPLETED	Safety Study of Continued Enzalutamide Treatment In Prostate Cancer Patients
NCT02405858	PHASE4	COMPLETED	A Study of Abiraterone Acetate in Metastatic Castration-Resistant Prostate Cancer Participants Who Responded Poorly to the First-line Combined Androgen Blockade Therapy
NCT02485691	PHASE4	COMPLETED	Cabazitaxel Versus the Switch to Alternative AR-targeted Agent (Enzalutamide or Abiraterone) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Patients Previously Treated With Docetaxel and Who Rapidly Failed a Prior AR-targeted Agent
NCT00268476	PHASE2/PHASE3	ACTIVE_NOT_RECRUITING	Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy
NCT01957436	PHASE3	ACTIVE_NOT_RECRUITING	A Phase III Study for Patients With Metastatic Hormone-naïve Prostate Cancer
NCT02257736	PHASE3	ACTIVE_NOT_RECRUITING	An Efficacy and Safety Study of Apalutamide (JNJ-56021927) in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC)
NCT03678025	PHASE3	RECRUITING	Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer
NCT03706365	PHASE2/PHASE3	ACTIVE_NOT_RECRUITING	A Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib (LY2835219) in Participants With Prostate Cancer
NCT03732820	PHASE3	ACTIVE_NOT_RECRUITING	Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer
NCT03748641	PHASE3	ACTIVE_NOT_RECRUITING	A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer
NCT03903835	PHASE3	RECRUITING	ProBio: A Biomarker Driven Study in Patients With Metastatic Prostate Cancer
NCT04446117	PHASE3	ACTIVE_NOT_RECRUITING	Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC
NCT04493853	PHASE3	ACTIVE_NOT_RECRUITING	Capivasertib+Abiraterone as Treatment for Patients With Metastatic Hormone-sensitive Prostate Cancer and PTEN Deficiency
NCT04497844	PHASE3	ACTIVE_NOT_RECRUITING	A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)
NCT04647526	PHASE3	ACTIVE_NOT_RECRUITING	Study Evaluating mCRPC Treatment Using PSMA [Lu-177]-PNT2002 Therapy After Second-line Hormonal Treatment
NCT04787744	PHASE2/PHASE3	RECRUITING	Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer
NCT05171816	PHASE3	ACTIVE_NOT_RECRUITING	Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer (China Cohort)
NCT05288166	PHASE3	ACTIVE_NOT_RECRUITING	A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)
NCT06120491	PHASE3	ACTIVE_NOT_RECRUITING	Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician’s Choice New Hormonal Agents
NCT06136624	PHASE3	RECRUITING	Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)
NCT06136650	PHASE3	RECRUITING	A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
NCT06520345	PHASE3	RECRUITING	The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global)
NCT06592924	PHASE3	RECRUITING	Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response
NCT06650579	PHASE3	RECRUITING	REVELUTION-2: Relugolix+Abiraterone Acetate (AA) Versus Leuprolide+AA Cardiac Trial
NCT06691984	PHASE3	ACTIVE_NOT_RECRUITING	Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)
NCT06764485	PHASE3	RECRUITING	A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator’s Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer
NCT07213674	PHASE3	RECRUITING	A Study of Xaluritamig Plus Abiraterone Versus Investigator’s Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
NCT07611110	PHASE3	RECRUITING	AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)
NCT00638690	PHASE3	COMPLETED	Abiraterone Acetate in Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy
NCT00887198	PHASE3	COMPLETED	Abiraterone Acetate in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer
NCT01517802	PHASE3	COMPLETED	A Study That Provides Long-term Safety Follow-up and Examines Long-term Exposure to Abiraterone Acetate
NCT01591122	PHASE3	COMPLETED	Study of Abiraterone Acetate Plus Prednisone in Patients With Chemo-naive Metastatic Castration-Resistant Prostate Cancer
NCT01695135	PHASE3	COMPLETED	A Study of Abiraterone Acetate Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Docetaxel-Based Chemotherapy
NCT01715285	PHASE3	COMPLETED	A Study of Abiraterone Acetate Plus Low-Dose Prednisone Plus Androgen Deprivation Therapy (ADT) Versus ADT Alone in Newly Diagnosed Participants With High-Risk, Metastatic Hormone-Naive Prostate Cancer (mHNPC)
NCT01949337	PHASE3	UNKNOWN	Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer
NCT02043678	PHASE3	COMPLETED	Radium-223 Dichloride and Abiraterone Acetate Compared to Placebo and Abiraterone Acetate for Men With Cancer of the Prostate When Medical or Surgical Castration Does Not Work and When the Cancer Has Spread to the Bone, Has Not Been Treated With Chemotherapy and is Causing no or Only Mild Symptoms
NCT02975934	PHASE3	COMPLETED	A Study of Rucaparib Versus Physician’s Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency

Clinical evidence (CIViC)

Variant × indication × effect (2 predictive associations from 2 curated evidence items):

Variant	Indication	Effect	Therapy	Level	CIViC
AR AR-V7	Salivary Gland Cancer	Resistance	Abiraterone Acetate	CIViC C	EID6954
AR V9 EXPRESSION	Prostate Cancer	Resistance	Abiraterone Acetate	CIViC E	EID5789

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).